secwatch.observer — SEC 8-K summary
======================================

Issuer:     NRX Pharmaceuticals, Inc. (NRXP)
CIK:        0001719406
Form:       8-K
Filed at:   2023-11-14T23:59:59+00:00
Accession:  0001104659-23-117735
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NRx Pharma Q3 net loss narrows to $6.1M; advances NRX-101 and ketamine plans
----------------------------------------------------------------------------

- Q3 net loss $6.1M vs $9.1M YoY; R&D expense $3.3M, G&A $2.5M; cash $8.9M.
- Near completion of Phase 2b/3 NRX-101 trial for treatment-resistant bipolar depression; top-line data expected shortly after last patient visit.
- Plan to submit NDA for IV ketamine (NRX-100) in Q1 2024; manufacturing partnership with Nephron signed.
- Received term sheet for up to $30M anchor financing for a ketamine-focused spinoff entity.
- Identified naked shorting disparities of ~1-1.5M shares; counsel instructed to demand closure of uncovered positions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719406/000110465923117735/0001104659-23-117735-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719406/000110465923117735/tm2330650d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-117735

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer